You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 50 No. 8, August 1993 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Articles
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (88)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients

Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia

John H. Krystal, MD; John P. Seibyl, MD; Lawrence H. Price, MD; Scott W. Woods, MD; George R. Heninger, MD; George K. Aghajanian, MD; Dennis S. Charney, MD

Arch Gen Psychiatry. 1993;50(8):624-635.


Abstract



Objective
This study evaluated whether alterations in serotonin function in schizophrenic patients could be demonstrated by comparing the reactivity to a serotonin partial agonist, m-chlorophenylpiperazine (MCPP) in patients and healthy subjects. This study also assessed whether stimulation of serotonin receptors influenced the symptoms of schizophrenia.

Design
Double-blind randomized comparison of MCPP (0.1 mg/kg, intravenously, administered over 20 minutes) and placebo effects in patients and healthy subjects.

Setting
Department of Veterans Affairs Medical Center, West Haven, Conn.

Patients and Healthy Subjects
Fifteen healthy subjects recruited by public advertisement and 12 schizophrenic inpatients who had been neuroleptic free for at least 2 weeks prior to entry into the study.

Main Outcome Measures
The principal outcome variable was the positive symptoms of schizophrenia operationally defined as the sum of scores on the four key items for schizophrenia on the Brief Psychiatric Rating Scale and the Brief Psychiatric Rating Scale thought disorder factor. Anxiety was assessed with a clinician-rated visual analog scale and plasma hormone levels were measured.

Results
m-Chlorophenylpiperazine significantly increased the positive symptoms of schizophrenia in patients but not healthy subjects. Patients and healthy subjects exhibited anxiety increases of comparable magnitude following MCPP. However, patients had higher baseline levels of anxiety and exhibited more prolonged anxiogenic responses to MCPP. Anxiety elevations did not correlate with increases in the four key symptoms in patients. Patients exhibited lower baseline prolactin levels compared with healthy subjects, but the two groups did not differ in their prolactin, growth hormone, and cortisol responses to MCPP.

Conclusions
Schizophrenics, the only psychotic patient group studied to date, are the first patient group to exhibit propsychotic responses to MCPP. These data provide further evidence that sertonin systems modulate positive symptoms in some schizophrenic patients.



Author Affiliations



From the Schizophrenia Biological Research Center, Department of Psychiatry, Yale University School of Medicine, West Haven (Conn) Veterans Affairs Medical Center, (Drs Krystal, Seibyl, and Charney), and the Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven (Drs Krystal, Seibyl, Price, Woods, Heninger, Aghajanian, and Charney).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality
Bradley and Dinan
J Psychopharmacol 2010;24:91-118.
ABSTRACT  

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity
Marquis et al.
J. Pharmacol. Exp. Ther. 2007;320:486-496.
ABSTRACT | FULL TEXT  

The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth et al.
Neuroscientist 2000;6:252-262.
ABSTRACT  

Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder
Southwick et al.
Arch Gen Psychiatry 1997;54:749-758.
ABSTRACT  

Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonist m-Chlorophenylpiperazine in Women with Premenstrual Syndrome and Controls
Su et al.
J. Clin. Endocrinol. Metab. 1997;82:1220-1228.
ABSTRACT | FULL TEXT  

Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal et al.
Arch Gen Psychiatry 1994;51:898-911.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.